In the multivariate model, the only variables associated with increased fracture risk was increasing age at scan decreased BMD total left and increased percentage body fat. All other factors did not significantly increase fracture risk in this cohort.

**Conclusion:** Our study suggests that many risk factors are associated with fragility fractures in those with smoking as their only risk factor; the best predictor was age at scan, BMD and gender. The percentage body fat association with increased fracture risk is quite surprising and would need further study. Percentage body fat is not currently included in the FRAX™ tool.

**Disclosure of Interests:** Dominic Beith: None declared, Marwan Bukhari

**Table 1. Univariate predictors of fracture in the smoking cohort * denotes significant prediction**

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Fracture (n=1663)</th>
<th>No Fracture (n=2433)</th>
<th>Odds ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>66.58</td>
<td>62.97</td>
<td>1.03</td>
<td>1.02, 1.05</td>
</tr>
<tr>
<td>Gender (no. of patients)</td>
<td>Male (383)</td>
<td>Male (469)</td>
<td>0.80</td>
<td>[0.69, 0.99]</td>
</tr>
<tr>
<td>Female (1280)</td>
<td>Female (1964)</td>
<td></td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>Height (cm)</td>
<td>162.26</td>
<td>162.41</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>71.16</td>
<td>71.16</td>
<td>1.00</td>
<td></td>
</tr>
<tr>
<td>L1-L4 BMD (g/cm²)</td>
<td>1.04</td>
<td>1.10</td>
<td>1.09</td>
<td>[0.13, 1.00]</td>
</tr>
<tr>
<td>Femoral neck BMD (left) (g/cm³)</td>
<td>0.82</td>
<td>0.87</td>
<td>0.88</td>
<td>[0.05, 0.12]</td>
</tr>
<tr>
<td>Total femur BMD (left) (g/cm³)</td>
<td>0.87</td>
<td>0.92</td>
<td>0.90</td>
<td>[0.07, 1.00]</td>
</tr>
<tr>
<td>% Body fat (g)</td>
<td>308.15</td>
<td>299.89</td>
<td>1.00</td>
<td>[1.00, 1.00]</td>
</tr>
</tbody>
</table>

**Background:** The prevalence of osteoporosis during celiac disease (CD) can range from 38% to 72%. In fact, it is a pathology that causes bone loss and is associated with a higher fracture risk compared to the general population.

**Objectives:** The aim of this work is to determine the frequency and factors associated with the decline in bone mineral density in adult subjects with CD.

**Methods:** This is a retrospective study, over a period of 4 years (from January 2014 to December 2018) and including patients followed for MC who had a measurement of bone mineral density (BMD) by DXA. Clinical, anthropometric and densitometric data (BMD at the femoral and vertebral site) were recorded.

**Disclosure of Interests:** None declared

**DISCUSSION:**

In 20 patients (47.6%) and low level of vitamin D (≤30ng/ml) in 32 patients (76.2%) associated with secondary hyperparathyroidism in 21 patients (51.2%). Mean creatinine clearance was 51.7±19.9ml/min. After evaluation, specific treatment of osteoporosis was started for 33 patients (78.6%); zoledronic acid (n=20), denosumab (n=8), alendronate (n=4) and teriparatide (n=1).

**Conclusion:** Systematic screening of osteoporosis seems to be useful in heart transplant patients. Osteoporosis was observed in half of these patients with a high frequency of low trauma fracture after heart transplantation, particularly in the first year.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2019-eular.7504
including the TUG test. TUG performance was considered low if it took 15 seconds or longer. A vertebral fracture assessment (VFA) image was obtained, which was subsequently scored for the presence of significant vertebral deformities. VF grade 1 were excluded.

Results: Eighty-four patients were included. The mean age of our patients was 62.29±8.27 years with an average body mass index (BMI) of 31.45±6.21 kg/m² [18.18-44.38]. According to the WHO classification 42 patients (50%) had osteoporosis. Among 84 women, 47 had a low TUG performance (and 12 patients who had normal TUG performance without statistically significant difference (p=0.08). VF were assessed in 22 subjects. VF were found in 20 patients with low TUG performance (42.5%). Compared with the group with normal TUG performance, subjects with low TUG performance had significantly higher number of fracture (p<0.001). A significant correlation was found between the number of VF and the score of get up and go test (Khi-2 test, p<0.001).

Conclusion: Our study found a strong relationship between TUG performance and prevalent vertebral fracture. Therefore evaluation of additional risk factors may improve the prediction of vertebral fracture in post-menopausal women.

Disclosure of Interests: None declared


FRIO486

NO IMPACT OF ANTI-RANK LIGAND AND PTH ANALOGUES ON CARDIOVASCULAR RISK IN IDIOPATHIC AND POSTMENOPAUSAL OSTEOPOROSIS: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

Laurence Ferrieres, Yannick Degboe, Michel Laroche, Arnaud Constantin, Adeline Ruyssen-Witvlieg, Hospital Center University Toulouse – Casselardit, Anzely, Toulouse, France

Background: Emerging evidence suggests a possible association between osteoporosis and cardiovascular disease.1,2 The mutual effects of drugs used in these two diseases are now a point of interest. Two meta-analyses have been conducted to explore the cardiovascular effects of bisphosphonates3,4. There is no review for other osteoporosis treatments, such as anti-rank ligand antibody and parathyroid hormone analogues.

Objectives: A literature review and meta-analysis of randomized controlled trials was conducted to address the impact of PTH analogues and anti-Rank Ligand on cardiovascular events and overall mortality in individuals with idiopathic osteoporosis.

Methods: A systematic literature review was conducted in December 2017 in the PubMed, Embase, Cochrane databases, and updated on PubMed in December 2018, by selecting trials including a treatment (anti-Rank ligand or PTH analogue) and a control group. We also conducted a search for abstracts of the French Rheumatology Society, American College of Rheumatology and European League Against Rheumatism annual meetings over the past 3 years. Relative risks and 95% confidence intervals for each event were estimated using the Inverse Variance fixed effects method. The main endpoints were the occurrence of cardiovascular events and all-cause of mortality.

Results: Of the 2782 reports initially found (503 articles via PubMed, 1309 via Embase, 474 via the Cochrane Library and 15 abstracts from annual meetings, 16 articles were used for the meta-analysis. All studies were randomized; no exploitable prospective cohort study was found. The number of adverse events of interest was available for 6 studies for the anti-Rank Ligand corresponding to 26 864 patient-years. After meta-analysis, there was no significant difference between the placebo group and the anti-Rank Ligand group for overall mortality (RR 0.79, 95% CI (0.60-1.04)), the combined cardiovascular endpoint (overall mortality, coronary artery disease and stroke: RR 0.95, 95% CI (0.78-1.16)), and the individual risk of coronary artery disease (RR 1.14, 95% CI (0.76-1.73); arrhythmia (RR 1.03, 95% CI (0.63-1.68)) and ischemic or hemorrhagic stroke (RR 1.03, 95% CI (0.72-1.47)). The number of adverse events of interest was available for 10 studies for the PTH analogue group, corresponding to 62 200 patient-years. Meta-analysis, there were no significant differences between the placebo group and the PTH analogue group for overall mortality (RR 0.69, 95% CI (0.35-2.29)), the combined endpoint (overall mortality, coronary artery disease and stroke: RR 0.71, 95% CI (0.37-1.36)), and the individual risk of coronary artery disease (RR 0.65, 95% CI (0.19-2.27)), arrhythmia disorders (RR 1.43, 95% CI (0.73-2.80)) and ischemic or hemorrhagic stroke (RR 0.60, 95% CI (0.19-1.96)).

Conclusion: The anti-Rank Ligand and the PTH analogues have no short-term impact on the cardiovascular risk and the overall mortality in postmenopausal osteoporosis. To better answer the question whether these treatments are able to reduce the long-term cardiovascular risk, further comparative studies with longer duration are required.

Disclosure of Interests: None declared


FRIO487

UTILITY OF TRABECULAR BONE SCORE(TBS) FOR FRACTURE RISK ASSESSMENT IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS

Helena Flores1,2, José Hernández-Rodríguez2, Africa Muxí2, Josep Lluís Carrasco3, Sergio Prieto-González2, Silvia Ruiz-Gaspa3, Maria C. Cid1, Ana Monegal1, Núria Guaschiba1, Pilar Peris1,1, Hospital Clinic, University of Barcelona, Metabolic Bone Diseases Unit. Department of Rheumatology, Barcelona, Spain;3Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Vasctulis Research Unit, Department of Autoimmune Diseases, Barcelona, Spain;4Hospital Clinic, University of Barcelona, Department of Nuclear Medicine, Barcelona, Spain; University of Barcelona, Biostatistics, Department of Basic Clinical Practice, Barcelona, Spain

Background: Glucocorticoid-induced osteoporosis (GIO) is the one of the more common forms of secondary osteoporosis (SO). Fractures in GIO frequently occur with higher than expected bone mineral density (BMD) values. The Trabecular Bone Score (TBS) is a gray-level textural index derived from DXA images that provides information about bone microarchitecture and fracture risk independently of BMD; therefore, TBS measurement could be useful for identifying patients with high fracture risk associated with glucocorticoid (GC) treatment.

Objectives: To analyse the clinical utility of TBS for fracture risk assessment in GC treated patients and compare it with BMD assessment, the gold-standard diagnostic test.

Methods: 127 patients on chronic GC treatment (≥5mg/day) were included (mean age 62±18 years, 63% women) in this cross-sectional study. The medical history and anthropometric data were collected, as well as measurements of bone metabolism parameters, bone densitometry (DXA) at lumbar spine and femur (considering OP when T-score ≤-2.5), TBS (considering degraded microarchitectue [DMA] with values <1.230) and dorsolumbar X-ray to assess vertebral fractures (VF). BMD and TBS

REFERENCES:


Disclosure of Interests: None declared